Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Simple item page
dc.contributorCompiled by the New Jersey State Libraryen_US
dc.date.accessioned2019-08-01T13:27:48Z
dc.date.available2019-08-01T13:27:48Z
dc.description.abstractYear: 2016; Chapter: 73
dc.identifier.urihttp://hdl.handle.net/10929.1/26498
dc.titleClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
dc.typeLegislative Historyen_US
lg.NJSA24:6B-1 & 24:6B-2en_US
lg.billNumberS2024en_US
lg.chapter073en_US
lg.njlhidL2016c73en_US
lg.synopsisClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
lg.titleClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
lg.yearEnacted2016en_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
L2016c73.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
Description:
L2016c73
Download

Collections

2016